Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 2 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 12226417

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  2. US 12215105

    HPK1 antagonists and uses thereof

    Nimbus Saturn, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  3. US 2025034260

    FCRN ANTAGONISTS FOR TREATMENT OF IGG-RELATED DISEASES AND DISORDERS

    ABLYNX NV [BE] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted
  4. WO 2025023852

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted
  5. WO 2025023851

    ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE

    BIAL PORTELA & CA SA [PT] · Granted Jan 30, 2025 · Expires Jan 25, 2045

    granted
  6. US 12208071

    Glucagon receptor antagonists

    Ligand Pharmaceuticals Incorporated · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  7. US 12201673

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  8. US 12202832

    Heterocyclic compounds having a calcium-sensing receptor antagonistic activity

    Takeda Pharmaceutical Company Limited · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  9. US 12171758

    Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto

    Neumora Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  10. US 12162861

    Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  11. US 12152038

    Vasopressin receptor antagonists and products and methods related thereto

    Neumora Therapeutics, Inc. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  12. US 12134609

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Nov 5, 2024 · Expires Oct 31, 2044

    granted
  13. US 12115255

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  14. US 12115166

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  15. US 12115254

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  16. US 12102640

    Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  17. US 12098141

    Bicyclic indazole glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  18. US 12097196

    Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  19. US 12098144

    Piperazine indazole glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Sep 24, 2024 · Expires Sep 19, 2044

    granted
  20. US 12091387

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  21. US 12090201

    Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  22. US 12071442

    Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists

    Nimbus Saturn, Inc. · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  23. US 12064433

    Pyridone A2R antagonists

    Arcus Biosciences, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  24. US 12065416

    cGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted